Baillie Gifford & Co. decreased its position in shares of STAAR Surgical (NASDAQ:STAA - Free Report) by 9.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,448,208 shares of the medical instruments supplier's stock after selling 469,918 shares during the quarter. Baillie Gifford & Co. owned about 9.11% of STAAR Surgical worth $138,829,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Clear Street Markets LLC acquired a new stake in STAAR Surgical during the 3rd quarter worth approximately $29,000. Evermay Wealth Management LLC raised its holdings in STAAR Surgical by 100.0% during the 1st quarter. Evermay Wealth Management LLC now owns 600 shares of the medical instruments supplier's stock worth $38,000 after buying an additional 300 shares during the period. Lazard Asset Management LLC raised its holdings in STAAR Surgical by 131.1% during the 1st quarter. Lazard Asset Management LLC now owns 684 shares of the medical instruments supplier's stock worth $54,000 after buying an additional 388 shares during the period. UBS Group AG raised its holdings in STAAR Surgical by 130.7% during the 2nd quarter. UBS Group AG now owns 805 shares of the medical instruments supplier's stock worth $57,000 after buying an additional 456 shares during the period. Finally, Captrust Financial Advisors raised its holdings in STAAR Surgical by 348.4% during the 2nd quarter. Captrust Financial Advisors now owns 825 shares of the medical instruments supplier's stock worth $59,000 after buying an additional 641 shares during the period. Institutional investors own 96.70% of the company's stock.
STAAR Surgical Stock Performance
STAA traded down $1.17 during trading on Wednesday, reaching $51.08. 749,321 shares of the stock were exchanged, compared to its average volume of 790,525. The stock's 50 day moving average price is $35.62 and its two-hundred day moving average price is $35.04. STAAR Surgical has a twelve month low of $26.66 and a twelve month high of $73.13. The stock has a market cap of $2.50 billion, a P/E ratio of 118.79 and a beta of 0.86.
STAAR Surgical (NASDAQ:STAA - Get Free Report) last announced its earnings results on Monday, February 26th. The medical instruments supplier reported $0.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.17 by ($0.01). The business had revenue of $76.27 million during the quarter, compared to the consensus estimate of $75.94 million. STAAR Surgical had a net margin of 6.62% and a return on equity of 8.73%. The company's revenue was up 19.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.04 EPS. Equities research analysts predict that STAAR Surgical will post 0.03 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several analysts have commented on STAA shares. William Blair upgraded shares of STAAR Surgical from a "market perform" rating to an "outperform" rating in a report on Thursday, April 4th. Needham & Company LLC reiterated a "hold" rating on shares of STAAR Surgical in a report on Thursday, April 4th. Canaccord Genuity Group lifted their price objective on shares of STAAR Surgical from $32.00 to $46.00 and gave the company a "hold" rating in a report on Monday. Mizuho lowered their price objective on shares of STAAR Surgical from $50.00 to $45.00 and set a "buy" rating on the stock in a report on Wednesday, February 28th. Finally, Stifel Nicolaus reiterated a "buy" rating and issued a $50.00 price objective on shares of STAAR Surgical in a report on Monday, April 1st. Seven research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $45.38.
Check Out Our Latest Stock Report on STAAR Surgical
Insider Activity
In other news, Director Aimee S. Weisner acquired 1,750 shares of the business's stock in a transaction that occurred on Thursday, March 14th. The stock was acquired at an average price of $38.11 per share, with a total value of $66,692.50. Following the completion of the transaction, the director now directly owns 10,864 shares of the company's stock, valued at approximately $414,027.04. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.10% of the stock is currently owned by company insiders.
STAAR Surgical Profile
(
Free Report)
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Further Reading
Before you consider STAAR Surgical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STAAR Surgical wasn't on the list.
While STAAR Surgical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
